Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista do Instituto de Medicina Tropical de São Paulo |
Texto Completo: | https://www.revistas.usp.br/rimtsp/article/view/221817 |
Resumo: | Multiple myeloma (MM) associated with Chagas disease is rarely described. This disease and its therapy suppress T cell and macrophage functions and increase regulatory T cell function, allowing the increase of parasitemia and the risk of Chagas Disease Reactivation (CDR). We aimed to analyze the role of conventional (cPCR) and quantitative Polymerase Chain Reaction (qPCR) for prospective monitoring of T. cruzi parasitemia, searching for markers of preemptive antiparasitic therapy in MM patients with Chagas disease. Moreover, we investigated the incidence and management of hematological diseases and CDR both inside and outside the transplant setting in the MEDLINE database. We found 293 studies and included 31 of them. Around 1.9–2.0% of patients with Chagas disease were reported in patients undergoing Stem Cell Transplantation. One case of CDR was described in eight cases of MM and Chagas disease. We monitored nine MM and Chagas disease patients, seven under Autologous Stem Cell Transplantation (ASCT), during 44.56±32.10 months (mean±SD) using parasitological methods, cPCR, and qPCR. From these patients, three had parasitemia. In the first, up to 256 par Eq/mL were detected, starting from 28 months after ASCT. The second patient dropped out and died soon after the detection of 161.0 par Eq/mL. The third patient had a positive blood culture. Benznidazole induced fast negativity in two cases; followed by notably lower levels in one of them. Increased T. cruzi parasitemia was related to the severity of the underlying disease. We recommend parasitemia monitoring by qPCR for early introduction of preemptive antiparasitic therapy to avoid CDR. |
id |
IMT-1_169ec0bde58e6b69c968dce1d4a14166 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/221817 |
network_acronym_str |
IMT-1 |
network_name_str |
Revista do Instituto de Medicina Tropical de São Paulo |
repository_id_str |
|
spelling |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and reviewMultiple myelomaChagas diseaseT. cruzi parasitemiaConventional PCRQuantitative PCRMultiple myeloma (MM) associated with Chagas disease is rarely described. This disease and its therapy suppress T cell and macrophage functions and increase regulatory T cell function, allowing the increase of parasitemia and the risk of Chagas Disease Reactivation (CDR). We aimed to analyze the role of conventional (cPCR) and quantitative Polymerase Chain Reaction (qPCR) for prospective monitoring of T. cruzi parasitemia, searching for markers of preemptive antiparasitic therapy in MM patients with Chagas disease. Moreover, we investigated the incidence and management of hematological diseases and CDR both inside and outside the transplant setting in the MEDLINE database. We found 293 studies and included 31 of them. Around 1.9–2.0% of patients with Chagas disease were reported in patients undergoing Stem Cell Transplantation. One case of CDR was described in eight cases of MM and Chagas disease. We monitored nine MM and Chagas disease patients, seven under Autologous Stem Cell Transplantation (ASCT), during 44.56±32.10 months (mean±SD) using parasitological methods, cPCR, and qPCR. From these patients, three had parasitemia. In the first, up to 256 par Eq/mL were detected, starting from 28 months after ASCT. The second patient dropped out and died soon after the detection of 161.0 par Eq/mL. The third patient had a positive blood culture. Benznidazole induced fast negativity in two cases; followed by notably lower levels in one of them. Increased T. cruzi parasitemia was related to the severity of the underlying disease. We recommend parasitemia monitoring by qPCR for early introduction of preemptive antiparasitic therapy to avoid CDR.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2024-02-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/22181710.1590/S1678-9946202466010Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e10Revista do Instituto de Medicina Tropical de São Paulo; v. 66 (2024); e10Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e101678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/221817/202721Copyright (c) 2024 Noemia Barbosa Carvalho, Vera Lúcia Teixeira de Freitas, Fernanda Salles Seguro, Rita Cristina Bezerra, Giancarlo Fatobene, Érika Yoshie Shimoda Nakanishi, Helena Visnadi, Gracia Martinez, Marjorie Vieira Batista, Vanderson Rocha, Frederico Luis Dulley, Sílvia Figueiredo Costa, Maria Aparecida Shikanai-Yasudahttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessCarvalho, Noemia Barbosa Freitas, Vera Lúcia Teixeira de Seguro, Fernanda Salles Bezerra, Rita Cristina Fatobene, GiancarloNakanishi, Érika Yoshie Shimoda Visnadi, Helena Martinez, Gracia Batista, Marjorie Vieira Rocha, Vanderson Dulley, Frederico Luis Costa, Sílvia Figueiredo Shikanai-Yasuda, Maria Aparecida 2024-03-20T14:09:28Zoai:revistas.usp.br:article/221817Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2024-03-20T14:09:28Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)false |
dc.title.none.fl_str_mv |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
title |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
spellingShingle |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review Carvalho, Noemia Barbosa Multiple myeloma Chagas disease T. cruzi parasitemia Conventional PCR Quantitative PCR |
title_short |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
title_full |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
title_fullStr |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
title_full_unstemmed |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
title_sort |
Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review |
author |
Carvalho, Noemia Barbosa |
author_facet |
Carvalho, Noemia Barbosa Freitas, Vera Lúcia Teixeira de Seguro, Fernanda Salles Bezerra, Rita Cristina Fatobene, Giancarlo Nakanishi, Érika Yoshie Shimoda Visnadi, Helena Martinez, Gracia Batista, Marjorie Vieira Rocha, Vanderson Dulley, Frederico Luis Costa, Sílvia Figueiredo Shikanai-Yasuda, Maria Aparecida |
author_role |
author |
author2 |
Freitas, Vera Lúcia Teixeira de Seguro, Fernanda Salles Bezerra, Rita Cristina Fatobene, Giancarlo Nakanishi, Érika Yoshie Shimoda Visnadi, Helena Martinez, Gracia Batista, Marjorie Vieira Rocha, Vanderson Dulley, Frederico Luis Costa, Sílvia Figueiredo Shikanai-Yasuda, Maria Aparecida |
author2_role |
author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Carvalho, Noemia Barbosa Freitas, Vera Lúcia Teixeira de Seguro, Fernanda Salles Bezerra, Rita Cristina Fatobene, Giancarlo Nakanishi, Érika Yoshie Shimoda Visnadi, Helena Martinez, Gracia Batista, Marjorie Vieira Rocha, Vanderson Dulley, Frederico Luis Costa, Sílvia Figueiredo Shikanai-Yasuda, Maria Aparecida |
dc.subject.por.fl_str_mv |
Multiple myeloma Chagas disease T. cruzi parasitemia Conventional PCR Quantitative PCR |
topic |
Multiple myeloma Chagas disease T. cruzi parasitemia Conventional PCR Quantitative PCR |
description |
Multiple myeloma (MM) associated with Chagas disease is rarely described. This disease and its therapy suppress T cell and macrophage functions and increase regulatory T cell function, allowing the increase of parasitemia and the risk of Chagas Disease Reactivation (CDR). We aimed to analyze the role of conventional (cPCR) and quantitative Polymerase Chain Reaction (qPCR) for prospective monitoring of T. cruzi parasitemia, searching for markers of preemptive antiparasitic therapy in MM patients with Chagas disease. Moreover, we investigated the incidence and management of hematological diseases and CDR both inside and outside the transplant setting in the MEDLINE database. We found 293 studies and included 31 of them. Around 1.9–2.0% of patients with Chagas disease were reported in patients undergoing Stem Cell Transplantation. One case of CDR was described in eight cases of MM and Chagas disease. We monitored nine MM and Chagas disease patients, seven under Autologous Stem Cell Transplantation (ASCT), during 44.56±32.10 months (mean±SD) using parasitological methods, cPCR, and qPCR. From these patients, three had parasitemia. In the first, up to 256 par Eq/mL were detected, starting from 28 months after ASCT. The second patient dropped out and died soon after the detection of 161.0 par Eq/mL. The third patient had a positive blood culture. Benznidazole induced fast negativity in two cases; followed by notably lower levels in one of them. Increased T. cruzi parasitemia was related to the severity of the underlying disease. We recommend parasitemia monitoring by qPCR for early introduction of preemptive antiparasitic therapy to avoid CDR. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-02-06 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rimtsp/article/view/221817 10.1590/S1678-9946202466010 |
url |
https://www.revistas.usp.br/rimtsp/article/view/221817 |
identifier_str_mv |
10.1590/S1678-9946202466010 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rimtsp/article/view/221817/202721 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo |
publisher.none.fl_str_mv |
Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo |
dc.source.none.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e10 Revista do Instituto de Medicina Tropical de São Paulo; v. 66 (2024); e10 Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e10 1678-9946 0036-4665 reponame:Revista do Instituto de Medicina Tropical de São Paulo instname:Instituto de Medicina Tropical (IMT) instacron:IMT |
instname_str |
Instituto de Medicina Tropical (IMT) |
instacron_str |
IMT |
institution |
IMT |
reponame_str |
Revista do Instituto de Medicina Tropical de São Paulo |
collection |
Revista do Instituto de Medicina Tropical de São Paulo |
repository.name.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT) |
repository.mail.fl_str_mv |
||revimtsp@usp.br |
_version_ |
1798951636649902080 |